What is Sagimet Biosciences Operating Cash Flow per Share?
Sagimet Biosciences's operating cash flow per share for the
three
months ended in Mar. 2024 was $-0.21.
Sagimet Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.99.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -69.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Sagimet Biosciences's Operating Cash Flow per Share or its related term are showing as below:
SGMT'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -69.1 Med: -50.75 Max: -32.4
Current: -69.1
During the past 5 years, Sagimet Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was -32.40% per year. The lowest was -69.10% per year. And the median was -50.75% per year.
SGMT's 3-Year OCF Growth Rate is ranked worse than 93.68% of 1235
companies
in the Biotechnology industry
Industry Median: 3.3
vs SGMT: -69.10
Sagimet Biosciences Operating Cash Flow per Share Historical Data
The historical data trend for Sagimet Biosciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sagimet Biosciences Operating Cash Flow per Share Chart
Competitive Comparison of Sagimet Biosciences's Operating Cash Flow per Share
For the Biotechnology subindustry, Sagimet Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Price-to-Operating-Cash-Flow falls into.
Sagimet Biosciences Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Sagimet Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Sagimet Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Sagimet Biosciences (Sagimet Biosciences) Business Description
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGMT has been successfully added to your 